Adage Capital Partners Gp, L.L.C. Gemini Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.31 - $2.01 $2.05 Million - $3.15 Million	1,564,865 Added 177.3%	2,447,477 $4.01 Million
Q1 2022 May 16, 2022	BUY	$1.29 - $3.08 $258,000 - $616,000	200,000 Added 29.3%	882,612 $1.23 Million
Q4 2021 Feb 14, 2022	SELL	$2.39 - $4.0 $179,250 - $300,000	-75,000 Reduced 9.9%	682,612 $1.99 Million
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $412,500 - $790,000	-125,000 Reduced 14.16%	757,612 $3.06 Million
Q2 2021 Aug 16, 2021	SELL	$6.32 - $14.02 $109,892 - $243,779	-17,388 Reduced 1.93%	882,612 $5.71 Million
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $10.2 Million - $16.2 Million	900,000 New	900,000 $12.2 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.